The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments
Authors
Angulo Cuesta, Javier; Manini , Claudia; López , Jose I.; Pueyo , Angel; Colás Escudero, María Begoña; [et al.]Identifiers
Permanent link (URI): http://hdl.handle.net/10017/59000DOI: 10.3390/cancers13092071.
ISSN: 2072-6694
Date
2021-04-25Affiliation
Universidad de Alcalá. Departamento de Biología de Sistemas. Unidad Docente Bioquímica y Biología molecularFunders
Instituto de Salud Carlos III
Comisión Europea
Bibliographic citation
Cancers, 2021, v. 13, n. 9, p. 2071-
Keywords
Renal cell carcinoma
Biomarker
DNA methylation
Epigenetics
Project
info:eu-repo/grantAgreement/ISCIII//PI19%2F00213/ES/IDENTIFICACIÓN Y CARACTERIZACIÓN DE NUEVOS MARCADORES DE CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN Y SU USO EN EL DISEÑO DE NUEVAS TERAPIAS
info:eu-repo/grantAgreement/ISCIII//PI16%2F00594/ES/LAS PROTEÍNAS EPIGENÉTICAS COMO DIANAS TERAPÉUTICAS EN EL TRATAMIENTO DE LOS TUMORES DE PRÓSTATA RESISTENTES A LA TERAPIA HORMONAL. IDENTIFICACIÓN Y VALIDACIÓN DE NUEVOS MARCADORES
Document type
info:eu-repo/semantics/article
Version
info:eu-repo/semantics/publishedVersion
Rights
© 2021 by the authors
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Access rights
info:eu-repo/semantics/openAccess
Abstract
Clear cell renal cell carcinoma (ccRCC) is curable when diagnosed at an early stage, but when disease is non-confined it is the urologic cancer with worst prognosis. Antiangiogenic treatment and immune checkpoint inhibition therapy constitute a very promising combined therapy for advanced and metastatic disease. Many exploratory studies have identified epigenetic markers based on DNA methylation, histone modification, and ncRNA expression that epigenetically regulate gene expression in ccRCC. Additionally, epigenetic modifiers genes have been proposed as promising biomarkers for ccRCC. We review and discuss the current understanding of how epigenetic changes determine the main molecular pathways of ccRCC initiation and progression, and also its clinical implications. Despite the extensive research performed, candidate epigenetic biomarkers are not used in clinical practice for several reasons. However, the accumulated body of evidence of developing epigenetically-based biomarkers will likely allow the identification of ccRCC at a higher risk of progression. That will facilitate the establishment of firmer therapeutic decisions in a changing landscape and also monitor active surveillance in the aging population. What is more, a better knowledge of the activities of chromatin modifiers may serve to develop new therapeutic opportunities. Interesting clinical trials on epigenetic treatments for ccRCC associated with well established antiangiogenic treatments and immune checkpoint inhibitors are revisited.
Files in this item
Files | Size | Format |
|
---|---|---|---|
role_epigenetics_cancers_2021.pdf | 692.5Kb |
|
Files | Size | Format |
|
---|---|---|---|
role_epigenetics_cancers_2021.pdf | 692.5Kb |
|
Collections
- BIOQBM - Artículos [137]